SFTPC and acute respiratory distress syndrome: Treatment of ARDS patients with a surfactant preparation containing recombinant human SP-C with an intact poly-valyl stretch (lusupultide) showed no mortality benefit [24, 26], but increased dose and/or changed protein and lipid composition may potentiate the clinical effect [39].